HOOKIPA announces non-binding discussions to acquire Poolbeg Pharma in all-share deal

HOOKIPA Pharma Inc.

Poolbeg shareholders to receive 0.03 HOOKIPA shares per share; expected ~55% ownership of combined entity before planned $30M fundraise.
Combined group to be Nasdaq-listed with operations in EU, UK, and US; Poolbeg to delist from AIM.
CVR for HOOKIPA shareholders tied to Gilead milestones (up to $407.5M) and HB-200 proceeds.
PUSU deadline under UK Takeover Code set for 30 January 2025; no certainty a firm offer will be made.
Fundraise of up to $30M to extend cash runway through year-end 2026, concurrent with deal completion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.